Background: Nowadays, an increasing number of discrete-choice experiments (DCEs) incorporate cost as an attribute. However, the inclusion of a cost attribute, particularly within collectively funded healthcare systems, can be challenging because health services or goods are generally not traded in a market situation and individuals are not used to paying for a service or a good at the point of consumption. Objective: To examine whether the inclusion of a cost attribute in a DCE results in different preferences regarding a surgical treatment for primary basal cell carcinoma (BCC) compared with a DCE without a cost attribute. Methods: A randomized study was performed in which the impact of a cost attribute on the general public's preferences ...
AbstractObjectiveCustomized care can be beneficial for patients when preferences for health care pro...
AbstractObjectiveRecent reviews of discrete choice methodology identified methodological issues warr...
Background. Responding to rising oncology therapy costs, multiple value frameworks are emerging. How...
Background: Nowadays, an increasing number of discrete-choice experiments (DCEs) incorporate cost as...
BACKGROUND Basal cell carcinoma (BCC) is a slowly growing nonmelanoma type of skin cancer that often...
Introduction As several studies have been conducted to elicit patients' preferences for cancer treat...
Introduction As several studies have been conducted to elicit patients' preferences for cancer treat...
Background: The SINS trial (Controlled Clinical Trials ISRCTN48755084; Eudract No. 2004-004506-24) i...
Background. Responding to rising oncology therapy costs, multiple value frameworks are emerging. How...
The cost attribute is of particular importance in discrete choice experiments, and this study is the...
BACKGROUND: This study sought to understand the preferences of patients with cancer and the trade-of...
AbstractThe cost attribute is of particular importance in discrete choice experiments, and this stud...
Background: The treatment of actinic keratosis (AK) is a potentially effective strategy for the pr...
Objective: Customized care can be beneficial for patients when preferences for health care programs ...
Objective: To assess the cost-effectiveness of Mohs micrographic surgery (MMS) compared with the sur...
AbstractObjectiveCustomized care can be beneficial for patients when preferences for health care pro...
AbstractObjectiveRecent reviews of discrete choice methodology identified methodological issues warr...
Background. Responding to rising oncology therapy costs, multiple value frameworks are emerging. How...
Background: Nowadays, an increasing number of discrete-choice experiments (DCEs) incorporate cost as...
BACKGROUND Basal cell carcinoma (BCC) is a slowly growing nonmelanoma type of skin cancer that often...
Introduction As several studies have been conducted to elicit patients' preferences for cancer treat...
Introduction As several studies have been conducted to elicit patients' preferences for cancer treat...
Background: The SINS trial (Controlled Clinical Trials ISRCTN48755084; Eudract No. 2004-004506-24) i...
Background. Responding to rising oncology therapy costs, multiple value frameworks are emerging. How...
The cost attribute is of particular importance in discrete choice experiments, and this study is the...
BACKGROUND: This study sought to understand the preferences of patients with cancer and the trade-of...
AbstractThe cost attribute is of particular importance in discrete choice experiments, and this stud...
Background: The treatment of actinic keratosis (AK) is a potentially effective strategy for the pr...
Objective: Customized care can be beneficial for patients when preferences for health care programs ...
Objective: To assess the cost-effectiveness of Mohs micrographic surgery (MMS) compared with the sur...
AbstractObjectiveCustomized care can be beneficial for patients when preferences for health care pro...
AbstractObjectiveRecent reviews of discrete choice methodology identified methodological issues warr...
Background. Responding to rising oncology therapy costs, multiple value frameworks are emerging. How...